A. Matikas (Solna, Sweden)
Karolinska Institutet - BioclinicumAuthor Of 1 Presentation
The crucial role of mentorship and fellowships (ID 315)
Presenter Of 1 Presentation
The crucial role of mentorship and fellowships (ID 315)
Moderator Of 2 Sessions
Author Of 1 Presentation
112P - Women with short survival after diagnosis of metastatic breast cancer - a population-based registry study
Abstract
Background
Despite therapeutic advances overall survival of metastatic breast cancer (MBC) at the population level has seen little improvement during the past decades. Short survival following diagnosis due to the biology of the disease or delays in access to cancer care might be contributing factors, which we aimed to investigate with this retrospective cohort study.
Methods
Women diagnosed with MBC between Jan 1st 2005 and Dec 31st 2016 were identified using the population-based Stockholm-Gotland breast cancer registry. Data regarding demographic and clinicopathologic characteristics, survival and treatment were extracted retrospectively from the registry and from patient charts. Patients succumbing within 90 days following diagnosis of MBC were identified and their characteristics were compared with patients with longer survival.
Results
Between 2005 and 2016, 3124 patients were diagnosed with MBC, of which 498 (16.1%) died within 90 days of diagnosis. Nearly half of them (n=233) did not receive any antitumoral treatment. Patients with short survival were older (73.4 years [26.5 – 97.6] vs. 65.9 years [21.8 – 99.5], p<0.001) and had more commonly estrogen receptor (ER)-negative breast cancer (32.7% vs. 18.2%, p<0.001). Although a temporal reduction in the percentage of patients dying within 90 days from diagnosis was noted, from 2005-2008 (19.5%) to 2009-2012 (14.2%) and 2013-2016 (15.6%), the difference was not significant (p for trend 0.067). In multivariable analysis higher age, negative ER status and short distant recurrence-free interval (DRFI) were independent predictors for short survival, whereas time period and de novo metastatic disease were not.
Conclusions
Nearly one out of six patients with MBC survived less than three months after diagnosis. Short survival after MBC diagnosis was associated with older age and aggressive tumor biology (ER-negativity, short DRFI). These data demonstrate a different spectrum of MBC at the population level, and can potentially inform on individualized follow-up strategies and treatment algorithms.
Legal entity responsible for the study
Karolinska University Hospital.
Funding
Karolinska University Hospital Stockholm region Swedish cancer society.
Disclosure
J. Bergh: Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Amgen; Research grant/Funding (institution): Bayer; Research grant/Funding (institution): Roche; Research grant/Funding (institution): Merck; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): Sanofi-Aventis; Honoraria (self): Up-to-date. T. Foukakis: Honoraria (self), Research grant/Funding (institution): Roche; Honoraria (self), Research grant/Funding (institution): Pfizer; Honoraria (self): Novartis; Honoraria (self): Up-to-date. All other authors have declared no conflicts of interest.